

COVID-19 Vaccination Program

Victorian update

Alicia Stark & Dr. Thomas Schulz


Engagement and Partnerships, COVID-19 Vaccination Program
COVID-19 Immunisation Program, DH

Wednesday 18 August 2021

COVID-19 doses administered in Victoria as of 17 August

Vaccinations by State or Territory of residence

Victoria



	Total	
At least one dose	48.11%	2,601,959
Fully vaccinated	26.68%	1,442,497
Population		5,407,574

Vaccination program updates

- **Expanded eligibility to include high risk young people aged 12-15**
 - Young people with specified medical conditions
 - Aboriginal and Torres Strait Islander young people
 - Young people aged 12-15 years will be given a two-dose schedule, with the normal minimum interval of 6 weeks between doses.
- **Access to AstraZeneca vaccine for people aged 18-39 years**
- **Mandatory vaccination in Residential Aged Care Facilities**
- **People with specified medical condition or people with significant disability can access reserved first dose Pfizer appointments**
- **Pregnant women should be routinely offered Pfizer at any stage of pregnancy**
- **State vaccination centres providing vaccines to people affiliated with a COVID-19 outbreak in schools**
- **First drive through vaccination centre in Australia has been established in Melton**



OFFICIAL

TGA safety updates

To 8 August 2021, approx. 13.7 million vaccine doses have been administered in Australia

- 9.1 million first doses and 4.6 million second doses.

Most frequently reported side effects

- a sore arm
- headache
- muscle pain
- fever and chills.

TGA investigated **swollen lymph nodes (lymphadenopathy)** following immunisation. Nothing unexpected was found.

TGA investigated reports of suspected **Guillain-Barre Syndrome (GBS)** following vaccination with AstraZeneca vaccine. Unable to establish a clear link between GBS and the AstraZeneca vaccine.

The protective benefits of vaccination against COVID-19 far outweigh the potential risks of vaccination

Side effects

Myocarditis and pericarditis

- More common in males under 30 years, after the second dose
- Most cases mild and patients have recovered quickly
- History of pre-existing conditions is not considered a contraindication to vaccination
- ATAGI and CSANZ emphasise the benefits of vaccination outweigh the rare risk of these conditions

Thrombosis with thrombocytopenia syndrome (TTS)

- TGA report (8 August) additional 11 reports of blood clots and low blood platelets. Assessment confirmed probable TTS. Ten of these were in individuals aged 60 years+. None of these cases were fatal.
- After AstraZeneca vaccine people need to be aware of the following symptoms
 - a persistent headache
 - persistent abdominal pain
 - lower limb pain, redness, swelling
 - tiny blood spots under the skin around injection site
- [Link to more information about TTS](#)

Consent for under 60s requesting AstraZeneca vaccine

- Only senior and experienced immunisers should be consenting and vaccinating those aged under 60 with AZ
- Vaccinators should complete the [AstraZeneca supplementary module](#)
- Vaccinators should be up to date with relevant information regarding TTS and ensure there is a comprehensive risk benefit discussion

Thank you for participating tonight

Department of Health and RACGP's next webinar

Wednesday 15 September, 6pm- 7pm

Topic - COVID-19 Immunisation and people with cancer



Department
of Health

For the latest information www.dhhs.vic.gov.au/coronavirus

Information is available in 50+ community languages at www.dhhs.vic.gov.au/translations

OFFICIAL